Appendix E Reporting proforma for pancreatic carcinoma

Surname: ....................................... Forename(s): .................................... Date of birth: ....…........... Sex:……

Hospital: .................………………. Hospital no: ...............…………….….. NHS no: ......…………..…...............

Date of surgery: ………………....... Date of report authorisation:……........ Report number: ....……….……......

Date of receipt: ……………………. Pathologist: …………………………… Surgeon:..………….………………...

Specimen type†

Kausch-Whipple’s pancreatoduodenectomy (PD) Pylorus-preserving PD

Total pancreatectomy Subtotal PD Left pancreatectomy

Other (specify) ………………………………………………………………….

Gross description

Site of tumour …………………..…… Maximum tumour diameter†……..…… mm

Macroscopic margin involvement: None Yes (R2) (which margin(s))…………………..

Identifiable named vessel(s) None Yes (which vessel)………………………

Background pathology None Yes (specify)………………………….…

Microscopic description

Histological type of tumour†: Ductal adenocarcinoma Other (specify)……...……..

Variant of PDAC (specify): .………………………………..

Differentiation†: Not applicable *(post-neoadjuvant therapy)*

Well (Grade 1) Moderate (Grade 2) Poor (Grade 3)

Assessment of size†: macroscopic appearances confirmed

measured histologically ……… mm

Maximum extent of invasion (pT)†:

pT0: No residual tumour

pTis: Carcinoma in situ

pT1a: Tumour 5 mm or less in greatest dimension

pT1b: Tumour greater than 5 mm but no more than 10 mm in greatest dimension

pT1c: Tumour greater than 10 mm but no more than 20 mm in greatest dimension

pT2: Tumour more than 20 mm but no more than 40 mm in greatest dimension

pT3: Tumour more than 40 mm in greatest dimension

pT4: Tumour involves coeliac axis, superior mesenteric artery and/or common hepatic artery

Response to neoadjuvant therapy†: Not applicable

CAP Grade 0 (No residual tumour) CAP Grade 1 (Moderate/marked response)

CAP Grade 2 (Minimal response) CAP Grade 3 (Poor/no response)

Margin status† Involved Not involved Not sampled Not applicable Clearance\*

Gastric transection margin: ….… mm

Duodenal transection margin: .…… mm

Pancreatic transection margin: ….… mm

Bile duct transection margin: ….… mm

SMV/SMA dissection margin: ….… mm

Posterior dissection margin: ….… mm

Anterior pancreatic surface: ….… mm

*\*Specify clearance of closest margin(s)*

Named vessel status:

*If named vessel involved, specify …………….*

Perineural invasion: Present Not identified

Regional lymph node status (pN)

Total number of nodes† ………

Number of involved nodes† ………

N stage†: pN0 (Regional lymph nodes not involved)

 pN1 (Metastases in 1 to 3 regional lymph nodes)

 pN2 (Metastases in 4 or more regional lymph nodes)

Distant metastasis (pM)†

Distant metastasis confirmed No Yes (pM1) specify site(s)……………………

Background pathology: Intraductal papillary mucinous neoplasm (IPMN)

Mucinous cystic neoplasmMCN) Other (specify)…………………… None

Comments

Pathological staging: (y)pT…. (y)pN…. (y)pM….. UICC version 8

Resection status†: Complete at all margins (R0) Incomplete microscopic (R1)

 Incomplete macroscopic (R2)

Signature:………………….…… Date:………………… SNOMED codes: T……… / M……….

†Data items that are currently part of the Cancer Outcomes and Services Dataset (COSD) version 8/9